Days af­ter re­port­ing PhI­II fail­ure, GSK pulls BC­MA drug from US mar­ket — but it's not giv­ing up en­tire­ly yet

GSK is pulling its BC­MA-tar­get­ing drug from the US mar­ket, end­ing a short, two-year run for a high-pro­file prod­uct that, among oth­er things, was hailed for mark­ing the phar­ma gi­ant’s re­turn to on­col­o­gy.

The com­pa­ny is ini­ti­at­ing the process for with­draw­al at the re­quest of the FDA, which in turn was based on the neg­a­tive read­out of a con­fir­ma­to­ry Phase III tri­al ear­li­er this month. In that tri­al, GSK’s Blenrep failed to ex­tend pro­gres­sion-free sur­vival over stan­dard of care for pa­tients with mul­ti­ple myelo­ma who have re­ceived at least two pri­or lines of ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.